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a b s t r a c t
Few studies have investigated cardiac arrhythmias during spaceﬂight. Atrial and ventricular premature
contractions, short-duration atrial ﬁbrillation, and non-sustained ventricular tachycardia were reported
by previous spaceﬂight programs. Some of these arrhythmias occurred following extravehicular activity
in space. Arrhythmias during spaceﬂight are related with hypokalemia, microgravity, changes in the
autonomic nervous system, and physical stress. Some astronauts have needed radiofrequency catheter
ablation for atrial arrhythmias. Future long-duration spaceﬂights beyond the Earth's orbit may expose
astronauts to signiﬁcant levels of radiation that affect the coronary arteries. Genetic tests for arrhythmias
might be added to the present cardiac screening examinations in the future.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The Space Shuttle has been retired and the International Space
Station (ISS) will be in use until 2020 (Fig. 1). Scientists and
engineers are thinking about a mission to Mars in the future.
Human exploration of space is at a turning point, and a number of
questions about the future of space programs around the world
continue to be discussed. Long spaceﬂights present serious physi-
cal challenges that need to be addressed.
Although the many changes in cardiovascular function during
spaceﬂight are well known from past studies, few studies have
investigated the cardiac arrhythmias that occur. It is fortunate that
no fatal arrhythmias have been reported so far, as such an
occurrence could lead to tragedy, resulting in cancellation of the
mission. The medical treatments available aboard spacecraft are
more limited than those available on Earth, where many medical,
physical, and technical resources are available to diagnose and
treat cardiac conditions. When a spacecraft travels far from the
Earth in the near future, few medical resources will be available
and any medical support response from Earth will entail delay.
On the ISS, Shuttle, and earlier missions, there were several
hypotheses about the causes of arrhythmias. Here, we will review
the studies that have dealt with cardiac rhythm problems in
spaceﬂight, and we will discuss the possibility of fatal arrhythmias
during future long-duration spaceﬂights and the implications with
respect to candidate examination. In addition, we will discuss non-
fatal arrhythmias, such as atrial ﬁbrillation (AF) and ventricular
premature contractions (VPCs), which may represent problems for
astronauts.
2. History of arrhythmias in astronauts
2.1. Apollo program (US)
Ventricular arrhythmias during spaceﬂight were ﬁrst reported
on ﬂights during the Apollo era (1961–1972) [1]. During the Apollo
15 mission, astronaut James Benson Irwin had bigeminal VPCs and
atrial premature contractions (APCs) [2,3]. The cause of those
arrhythmias was associated with a decrease in his total body
potassium level. The astronauts on that mission tended not to
consume a sufﬁcient amount of potassium [4]. One other crew-
member also exhibited some arrhythmias (VPCs and APCs); how-
ever, they were far less serious than those suffered by astronaut
Irwin [2].
2.2. Skylab program (US)
During the Skylab (1973–1979) missions, American crewmem-
bers exhibited some forms of arrhythmias. Most of those rhythm
disturbances were isolated VPCs. However, one crewmember
experienced a ﬁve-beat run of VPCs during lower-body negative
pressure (LBNP) training. The LBNP technique was used as a
countermeasure to post-spaceﬂight orthostatic intolerance. In
this technique, the lower body is enclosed in an airtight contai-
ner from which air is removed to decrease the pressure and
draw blood to the legs and lower body, “simulating” a 1-g
environment and maintaining some tolerance to those conditions
[5]. Another crewmember had APCs during rest and exercise
following LBNP.
A crewmember who had carried out an extravehicular activity
(EVA), otherwise known as a “spacewalk” (Fig. 2), subsequently
had an episode of multifocal VPCs [6,7]. During EVA, astronauts
conduct various tasks outside the spacecraft in a hostile environ-
ment that includes decompression, limited ﬂuid intake, psycholo-
gical stress, and physical exertion. The duration of some EVAs has
extended to eight hours from start to ﬁnish. EVAs were performed
throughout the Apollo, Skylab, and Space Shuttle programs, and
many have been performed as part of the ISS program. In fact,
EVAs were instrumental in building the ISS. Electrocardiograms
are always monitored during EVAs [8,9].
2.3. MIR program (Russian Federation)
An episode of ventricular tachycardia (VT) was recorded during the
MIR era (1986–2001). A 14-beat episode of VT (maximum rate 215
beats per minute) occurred during a long-duration spaceﬂight (Fig. 3)
[10]. The mechanism of that event was not clear. However, possible
factors could have been an electrolyte disturbance (calcium,Fig. 1. International Space Station (ISS). Photo courtesy of JAXA/NASA.
T. Anzai et al. / Journal of Arrhythmia 30 (2014) 139–149140
potassium), autonomic alterations, or perturbations associated with
the change in the ventricular mass or volume [10]. There have been a
total of 75 arrhythmias and 23 conduction disorders reported by the
Russian medical community to NASA. The second most frequent
medical problem during the MIR program era was arrhythmias [11].
2.4. Space Shuttle program (US)
Nine out of 14 Shuttle crewmembers from 1983 to 1985, who
did not have any episodes of arrhythmias before their ﬂight,
demonstrated arrhythmias during the EVAs [12]. One possible
cause of the cardiac electrical disturbances observed during the
Shuttle EVAs in 1983–1985 may have been catecholamine levels.
Although various studies have been conducted, their actual role
and inﬂuence during the EVA remain inconclusive [3].
3. Effects of spaceﬂight on the heart
There is little information on the cardiovascular responses to
long-duration spaceﬂight, especially from the ISS era. However,
from past studies, we know that spaceﬂight has many effects on
the human heart. For example, gravity affects the distribution of
human bodily ﬂuids. Entering the microgravity environment
causes a large (1–2 L) shift of ﬂuid towards the head, increasing
the cardiac size and stroke volume soon after launch. [13]. After
the 10-day second German Spacelab Mission in 1993, the left
ventricular (LV) mass of the crewmembers had decreased by
1276.9% [14]. During the STS-107 space mission, the cardiac
output was measured by using noninvasive rebreathing equip-
ment [15]. In that study, cardiac output immediately increased by
2977%, from 6.670.7 to 8.470.9 L/min, after launch. Another
study showed that when astronauts returned to Earth, they had
lost a total of 10%–20% of their blood volume and exhibited
increased orthostatic intolerance [16].
4. Potential cardiovascular problems during long-duration
spaceﬂights
There are several characteristics of long-duration spaceﬂight
that could cause cardiac arrhythmias.
4.1. Prolongation of the QT interval and other ECG changes in space
Prolongation of the QT interval on the ECG is associated with an
increased risk of torsades de pointes (TdP), a myocardial repolar-
ization disorder [17]. Some studies have reported that corrected
QT intervals (QTc) increased during long-duration spaceﬂights on
board the MIR and the ISS missions. After a long-duration ﬂight,
24% of the QTc intervals were over 0.450 [18], indicating that the
ventricular repolarization process may be altered during long-
duration spaceﬂight.
A number of factors could contribute to this phenomenon. First,
a greater incidence of bradycardia has been observed during long-
duration spaceﬂights than during short-duration spaceﬂights,
which could result in prolongation of the QT interval. Second, on
the ISS missions, the crewmembers were able to use medications
Fig. 3. Non-sustained ventricular tachycardia (VT) during a long-duration spaceﬂight. Non-sustained VT (215 bpm) was observed on the Holter ECG (modiﬁed leads V1 and
V5) during the MIR mission. The 3 panels are continuous. The VT started with a ventricular premature contraction. Reproduced with permission from Fritsch-Yelle et al. [10].
Fig. 2. Extravehicular activity (EVA). Photo courtesy of NASA/JAXA.
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that affect the QT interval, such as ciproﬂoxacin, haloperidol,
propranolol, verapamil, azithromycin, sertraline, and nortriptyline.
Third, a previous study showed that a long spaceﬂight was
followed by changes in the autonomic nervous system [19], which
could also inﬂuence the QT interval.
Microvolt T-wave alternans (MTWA) is a recent non-invasive
method for analyzing ECGs and predicting sudden cardiac death
(SCD). MTWA can also assess the cardiac repolarization process.
One study showed that MTWA increased signiﬁcantly from 17%
to 42% during a 9- to 16-day head-down tilt bed (HDTB) test
(Fig. 4) [20]. On the other hand, another study did not indicate any
change in QTc itself after 90 days of HDTB, though the spatial QRS-
T angle signiﬁcantly increased and spatial ventricular gradient
signiﬁcantly decreased [21]. Moreover, Golubchikova and collea-
gues reported no pathology in the myocardial bioelectrical activity
in 59 astronauts during the MIR missions that lasted over 6 months
[22]. In view of the contradictory results, a deﬁnite conclusion
regarding ECG changes cannot be reached.
4.2. Radiation
The terrestrial environment protects humans from exposure to
space radiation [23]. However, long-duration spaceﬂight missions will
require humans to live outside the Earth's atmosphere and geomag-
netic ﬁeld. Exposure to a single physical dose of 0.1 or 0.2 Gy of 56Fe
ions, which is equivalent to the radiation dose of the orbital region, has
proven to result in degenerative changes in mouse coronary arteries
15 months after exposure to radiation [24]. This suggests that long
exposure to Fe ions in space may result in cardiovascular injury later in
life, including structural damage to the coronary arteries. Until now,
astronauts have orbited relatively close to the surface of the Earth,
where there is less danger of radiation exposure, but a 1000-day
exploratory mission to Mars would require 400 days in space and 600
days on the surface of Mars. For a 40-year-old man on a mission to
Mars, the excess risk of death from radiation exposure is estimated to
be between 1.3% and 13% [25]. Clearly, the cardiac effects of long-term
space radiation on astronauts need to be carefully considered when a
long spaceﬂight is being planned.
4.3. Psychological stress
Another potential cause of arrhythmia during long-duration
spaceﬂight is psychological stress. Spaceﬂight, especially long-
duration spaceﬂight, is known to be very stressful, and living in
this dangerous environment for long periods of time is also known
to cause serious psychosocial and psychiatric effects in space
crews [26]. Both clinical and epidemiological studies indicate that
the incidence of acute cardiac infarction, fatal arrhythmia, and SCD
is increased by emotional stress. For example, intense stressors,
such as earthquakes, have been associated with increased cardiac
mortality [27]. In one study of patients with implantable cardio-
verter deﬁbrillators, the destruction of the World Trade Center in
New York City on September 11, 2001, was associated with a
signiﬁcant increase in episodes of tachyarrhythmias among
patients living either in the New York City area or elsewhere
[28,29]. It therefore seems likely that the psychological stress of
long spaceﬂights may cause fatal arrhythmias; the cardiac effects
of psychological stress on astronauts should be studied in detail.
4.4. Hypokalemia
Potassium deﬁciency may cause fatal arrhythmias during long
spaceﬂights in the future. The total body potassium level is
approximately 45 mmol/kg [30]. The potassium intake is normally
40–120 mmol (1.6–4.8 g) per day, most of which is then excreted
in the urine. A lower potassium intake is associated with a
reduction in serum potassium [31]. Potassium loss was observed
in the Apollo crewmembers. Increased levels of urinary potassium
during spaceﬂight may be the result of muscle atrophy and an
inadequate potassium intake [30]. On the ISS missions, the
potassium intake of the crewmembers was 3.2 g/day on average,
which is lower than the recommended daily amount of 3.5 g for
ISS crewmembers [30]. For future long-duration spaceﬂights, such
as a Mars mission, control of potassium intake needs to be much
stricter for the prevention of fatal arrhythmias.
5. Possible fatal arrhythmias during long-duration
spaceﬂights
In exploratory spaceﬂights, the possibility of a cardiac event
would be a risk on long missions, such as a Mars mission. “The 2004
NASA Bioastronautics Critical Path Roadmap identiﬁed the occur-
rence of serious cardiac dysrhythmias and diminished cardiac and
vascular function as the primary cardiovascular risks of spaceﬂight”
[32]. During short to moderate spaceﬂights, the possibility of a life-
threatening event such as a cardiac arrest is about 1% per year [33].
The likelihood of a need for cardiopulmonary resuscitation (CPR) in
spaceﬂight is very low, but still exists.
Recent data suggest that SCD accounts for approximately 20%
of the total mortality in the United States and other industrialized
countries, with an incidence in the US of over 300,000 cases
annually [34]. SCD can occur because of fatal arrhythmias or other
cardiac problems. Since ventricular ﬁbrillation (VF) and pulseless
VT are the major causes of SCD, preventing VF and VT is very
important for long-duration spaceﬂights. Exercise can be a trigger
for SCD with people who have cardiovascular disease. The risk for
SCD in young athletes with cardiovascular disease is 2.5 times
higher than that in non-athletes. More than 90% of SCDs occur
during or immediately after a training session or competition
[35,36]. Astronauts usually get plenty of exercise in the ISS during
their missions. The actual crewmembers of the ISS (who spend
6 months in space) spend 2–3 h daily exercising (Fig. 5) [8].
Astronauts should monitor their ECGs during training in space.
6. Non-fatal arrhythmias in space
6.1. Atrial ﬁbrillation
AF has been experienced in short-duration spaceﬂights; it is
also a risk in long spaceﬂights. AF affects approximately 2.2 million
Fig. 4. Head-down tilt bed rest (HDTB). Six-degree head-down bed rest can be an
analog of the microgravity environment in humans. Therefore, researchers have
used long-term 61 head-down bed rest to simulate long spaceﬂight. Photo courtesy
of JAXA.
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patients in the US [37]. AF is the most common rhythm disorder
among US patients hospitalized with a primary diagnosis of
cardiac arrhythmia. The prevalence of AF is higher in men than
in women (1.1% versus 0.8%), and this discrepancy is observed
among every age group [37]. The medical certiﬁcation of ISS
crewmembers considers supraventricular tachycardia, including
AF, to be grounds for medical disqualiﬁcation from ISS missions
[38]. The prevalence of AF in astronauts is the same as in the
general population, but is higher in younger astronauts than in the
younger general population [39]. In a cohort study of NASA
astronauts, 5 out of 100 astronauts active since 2001 underwent
radiofrequency ablation treatment for atrial arrhythmias [39]. The
environmental changes can cause atrial electrophysiological char-
acteristics in astronauts, which predispose them to AF.
A meta-analysis of studies of AF among athletes has shown that
the risk of AF is signiﬁcantly higher in athletes than in the general
population [40], and that vigorous aerobic activity exceeding
200 min per week results in an increased risk of AF. Most
astronauts exercise well beyond 3 h per week, putting them at
risk for AF, much like athletes [39].
AF occurs in up to 60% of heavy drinkers with or without an
underlying alcoholic cardiomyopathy [41]. Most cases occur dur-
ing a period of increased alcohol intake. This phenomenon has
been termed “the holiday heart syndrome.” Even modest amounts
of alcohol can trigger AF in some patients. The Johnson Space
Center (JSC) Space Medicine management commented that both
astronauts and ﬂight surgeons are aware that alcohol intake
should be minimized. However, the JSC Flight Medicine Clinic's
evaluation of risk factors for the astronaut group with atrial
arrhythmias found no link to alcohol intake [39].
Exposure to the space environment can increase the risk of
both paroxysmal AF and chronic AF. Paroxysmal AF may be
induced by rapid hemodynamic changes and ﬂuid shifts when
the rocket is launched or enters outer space. The changes in the
autonomic balance and atrial pressure could also affect the atrial
electrophysiological characteristics and predispose the astronaut
to AF. However, the AF may be temporary and normal sinus
rhythm may be restored spontaneously. On the other hand,
chronic radiation exposure may affect cardiac remodeling, which
is one of the main causes of chronic AF [39].
6.2. Ventricular premature contractions
VPCs are another category of non-fatal arrhythmias. VPCs are
common and occur in a broad spectrum of the population, including
patients without structural heart disease or any form of cardiac
disease. Since the Apollo program era, there have been many reports
of VPCs on space missions. However, in no case have they interfered
with any mission. Of course, coronary artery disease should be ruled
out by performing cardiac computed tomography during screening.
VPCs may not be a substantial risk factor for long-duration
spaceﬂights.
7. Current cardiac screening
Several techniques are available for the screening of fatal and
non-fatal arrhythmias (Table 1).
At present, selection (select-out) evaluations consist of a cardio-
vascular screening examination of blood pressure (recumbent and
orthostatic position), heart rate measurement, and a cardiac physical
examination. This screening protocol includes 24 h-Holter monitoring,
resting echocardiogram, resting 12-lead ECG, and Bruce protocol
treadmill stress test [42]. Usually the astronauts selected have to
undergo training for a long time, and for long-duration spaceﬂights
they will need to undergo coronary screening before their launch.
Therefore, the coronary artery calcium score and high-sensitivity
C-reactive protein level are also included in the protocol [43]. Select-
out criteria include a clinical history of major congenital abnormalities,
evidence of ischemic heart disease (IHD), persistent tachycardias,
Table 1
Summary of cardiac examinations for the selection of astronauts.
Present cardiac screening [42,43,73]a (From MED. Vol. C)
I Physical exams (heart sound, blood pressure) and clinical medical history
II Resting 12-lead ECG
III 24-h Holter monitoring
IV Resting echocardiogram/color Doppler study
V Bruce protocol treadmill stress test
VI Blood test (total cholesterol, HDL, LDL, TG, high-sensitivity CRP)
VII Coronary artery calcium score
Potential future cardiac screening
I Genetic tests
II Multi-detector row computed tomography
III Cardiac magnetic resonance imaging
IV Signal-averaged electrocardiogram
V Implantable loop recorder
VI Electrophysiological study
VII Exercise echocardiogram
a From Medical Evaluation Document (MED) Volume C: Medical Standards and Certiﬁcation Procedures for Space Flight
Participants. International Space Station Program, Rev. 1.0, May 2007 [73]. HDL, high-density lipoprotein; LDL, low-density
lipoprotein; TG, triglycerides; CRP, C-reactive protein.
Fig. 5. Exercise in the ISS during missions. Astronauts exercise with a cycle
ergometer having a vibration isolation and stabilization system (CEVIS). Photo
courtesy of JAXA/NASA.
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arrhythmias, conduction defects, ECG abnormalities, thrombophlebitis,
deep venous incompetence, varicose veins, peripheral vascular disease,
cardiac tumors, valvular disorders or signiﬁcant hypertrophy, dilation
of the heart, or a reduced ejection fraction. Additionally, active
pericarditis, myocarditis, and endocarditis are also listed in the
select-out criteria [42].
8. Future potential cardiac examinations for long-duration
spaceﬂights
8.1. Screening variations in accordance with the candidate's age and
gender
The distribution of the cardiac causes of SCD varies with the
age, population studied, and geography. While IHD accounts for
62% of SCD among the general population in the US [44], the
distribution differs amongst younger athletic patients without
prior heart disease. In the US, hypertrophic cardiomyopathy
(HCM) is the single most common cause of SCD in young athletes,
accounting for 35%–50% of the cases [35]. In France, the most
common cardiovascular causes were HCM (10%), primitive VF (8%),
and congenital coronary artery anomalies (6%) (Fig. 6) [36].
The largest cause of sudden cardiac arrest is IHD in men and
women. However, IHD is the principal diagnosis in the majority of
men. In contrast, the incidence of non-IHD in women, including
dilated cardiomyopathy (19%) and valvular heart disease (13%), is
greater than in men (Fig. 7) [44].
Therefore, screening tests depend on the candidate's age and
gender. In the astronaut selection process, men should undergo
more detailed coronary screening, while echocardiography should
be performed in greater detail in women.
8.2. Genetic tests
Several diseases can cause SCD in an individual with a normal
heart structure during long-duration spaceﬂight. However, there
are diagnostic limitations. In the past, the etiology of many of
those deaths was unknown and was deemed “idiopathic”, whereas
now some of them are recognized as genetic or electrophysiolo-
gical disorders. Examples of these are congenital long-QT syn-
drome, Brugada syndrome, and arrhythmogenic right ventricular
cardiomyopathy (ARVC).
8.2.1. Congenital long-QT syndrome
Many genes have been implicated in causing congenital long-
QT syndrome (LQTS): KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2 KCNJ2,
CACNA1C, CAV3, SCN4B, AKAP9, SNTA1, and KCNJ5 encode subunits
of cardiac ion channels, while ANK2 encodes cardiac ankyrin,
which anchors ion channels to the cell membrane [45].
8.2.2. Brugada syndrome
Another disease of concern in relation to long-duration space-
ﬂights is Brugada syndrome. Brugada syndrome is characterized
by ST-segment elevation in the right precordial leads and is
unrelated to ischemic or structural heart disease [46]. It is a cause
of SCD in individuals with a structurally normal heart. Sudden
death during the night has been noted in a small percentage of
young males from Southeast Asia. Although typically the cause of
death could not be determined in those young men, it is reported
that Brugada syndrome was closely related to SCD among young
males in Thailand [47]. This disorder has been linked to mutations
in the SCN5A gene, all of which have been shown to reduce the
magnitude of the cardiac Naþ current through a variety of
mechanisms [47].
8.2.3. Arrhythmogenic right ventricular cardiomyopathy
Another genetic arrhythmia that could be devastating on a
space mission is ARVC. It was ﬁrst described in 1977 and is
characterized by the replacement of the right ventricle (RV) free
wall with fat or ﬁbrous tissue [48]. The ﬁbrofatty replacement of
the RV myocardium initially produces typical regional wall motion
abnormalities that later become global, producing RV dilation. The
tissue replacement can also involve part of the left ventricle with
relative sparing of the septum [49]. Patients often present with
symptomatic VT, and the risk of sudden death is approximately
2.5% per year. ARVC is an important cause of SCD in young adults
and athletes. ARVC is a genetic disease, and a familial history has
been reported in 30%–50% of cases [48]. For this reason, candidates
should be required to submit a detailed familial history in addition
to undergoing a genetic work-up. The prevalence in the general
population is estimated to be 1:2000 [50]. However, it is some-
times difﬁcult to detect ARVC by performing echocardiography
during the early phase of tissue replacement. The selection of
astronauts for Mars missions should include cardiac computed
tomography and magnetic resonance imaging (MRI) to rule out
any cardiac abnormalities in the candidates.
Fig. 6. Cardiovascular abnormalities in young competitive athletes in France. See the text (Section 5) for the discussion. Reproduced with permission from Marijon et al. [36].
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8.2.4. Atrial ﬁbrillation
In an analysis of 2243 offspring in the Framingham Heart Study,
those with parental AF had a signiﬁcantly higher incidence of
developing AF than those without parental AF (4.1% versus 2.7%,
adjusted odds ratio 1.85) [51]. Recent genome-wide association
studies identiﬁed single-nucleotide polymorphisms at loci 1q21,
1q24, 4q25, 5q31, 7q31, 9q22, 10q22, 14q23, 15q24, and 16q22 that
are associated with AF [52,53]. Genetic tests for AF, at least at 4q25
(PITX2), may be also needed when astronauts are selected for long
missions. If the astronaut candidates have an AF history, they
should be eliminated from the selection process. Astronauts in
training may undergo catheter ablation of AF. Some studies have
reported that the rate of recurrence is 10–30%. Follow-up methods
to determine if there will be recurrence are controversial among
the NASA medical panelists [39], who stated that no tests, includ-
ing an electrophysiological study (EPS), are able to guarantee that
an ablated astronaut will never develop AF again. However, the
panel concluded that complete pulmonary vein isolation reduces
the recurrence rate of AF [39], and that a follow-up EPS conﬁrming
complete pulmonary vein isolation should be a prerequisite for
qualifying the astronaut.
An implantable loop recorder is a good monitoring device that
can help in the decision whether an astronaut who has undergone
catheter ablation for the treatment of AF can ﬂy again [54]. These
devices can be useful in the evaluation of AF recurrences when
symptoms are infrequent (e.g., less than once per month) [55]. In
patients with infrequent symptoms, conventional non-invasive
testing is often negative or inconclusive.
8.3. Imaging technologies
8.3.1. Multi-detector row computed tomography
Since 1999, the temporal resolution of mechanical multi-
detector row computed tomography scanners (MDCT) has
improved sufﬁciently. MDCT can create cardiac images of the
beating heart with no or little motion artifact. This improvement
has been exciting and revolutionary because prior to the appear-
ance of MDCT coronary angiography was the only way to observe
coronary sclerosis. MDCT can detect diseases that cause fatal
arrhythmias and SCD, such as coronary arteriosclerosis, anomalous
communication of the coronary arteries, patent foramen ovale,
and ARVC.
Japanese astronaut selection took place during 2008–2009. In
the ﬁnal selection stage, a 320-line MDCT was performed [56]. The
320-line MDCT can reduce the radiation by 40% compared to the
previous 64-line MDCT.
8.3.2. Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (MRI) can be very useful
in the assessment of patients with possible or conﬁrmed IHD.
Cardiac MRI provides a dimensionally accurate and three-
dimensional perspective of the heart, so it has been considered
by many to be the gold standard for measurements of the left and
right ventricular ejection fractions, volumes, and myocardial mass.
It can detect regional wall motion abnormalities and high-energy
phosphate abnormalities in ischemic tissue.
9. Currently available treatments for emergency cases in
spaceﬂight
Astronaut Crew Medical Ofﬁcers (CMO) aboard the ISS receive
40–70 h of medical training, including CPR training, within 18
months preceding their mission (Fig. 8). However, opportunities
for crew to refresh their knowledge of CPR training in ﬂight are
limited, because of the busy time schedule. Therefore, compliance
with the CPR guidelines may be uncertain [57]. Astronauts need to
take more courses that are intensive in CPR so that it becomes
1. CAD: coronary artery disease
2. DCM: dilated cardiomyopathy
3. VHD: valvular heart disease
4. Spasm: coronary vasospasm
5. RV: right ventricular
Fig. 7. Structural heart disease in cardiac arrest survivors. Pie charts depicting the proportion of underlying cardiac disease among men and women who survive out-of-
hospital cardiac arrest. Reproduced with permission from Albert et al. [44].
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second nature to them. If they do not have enough training, it
could become a matter of life or death in an emergency case on
the ISS.
NASA and the Russian Federal Space Agency each supply
medical equipment for the ISS. NASA's medical apparatus is called
the crew health care system (CHeCS). The Health Maintenance
System (HMS) is one part of the CHeCS. It is an in-ﬂight preventive
medical system that can diagnose and treat patients. It can also be
used to treat severe disease on the ISS [58]. The HMS division
maintains the crews' health by using various packs in the ISS from
the CHeCS rack. The HMS is divided into 6 sections as follows [59].
9.1. Advanced life support pack (ALSP)
The ALSP provides the necessary equipment to save a crew-
member's life with equipment for Advanced Cardiac Life Support
and Basic Trauma Life Support. For example, it contains an
automated external deﬁbrillator, an airway supply pack, emer-
gency surgery pack, IV administration pack, drug pack, and blood
pressure cuffs.
9.2. Ambulatory medical pack (AMP)
The AMP is a kind of non-emergency pack and a ﬁrst aid kit. It
has supplies for analyzing blood samples, treating minor wounds,
and performing dental checks.
9.3. Crew contamination protection kit (CCPK)
The CCPK protects the crew from exposure to environmental
contaminants. It has supplies such as eyewash.
9.4. Crew medical restraint system (CMRS)
The CMRS was and continues to be used to stabilize patients
who need to be restrained. This makes it easier to transport
patients and stabilize the spine. Another important use of the
CMRS is for electrical isolation with deﬁbrillation use.
9.5. Respiratory support pack (RSP)
The RSP is used to provide low ﬂow 100% oxygen to the patient
by using the Ambu bag found in the ALSP.
9.6. Health maintenance system ancillary support pack (HASP)
The HASP is used to provide and resupply the above mentioned
units. It contains items such as saline, battery packs, and
ultrasound gel.
10. Treatment of fatal arrhythmias in hospitals today
In 1891, Dr. Friedrich Maass issued the ﬁrst documented
research concerning chest compressions for humans. The Amer-
ican Heart Association (AHA) formally subscribed to CPR in 1963
and published standardized guidelines for its instruction in 1966
[60]. ACLS guidelines have changed over the decades, based on a
combination of scientiﬁc evidence and expert consensus. For
example, the AHA developed the most recent ACLS guidelines in
2010 by using a comprehensive review of the resuscitation
literature. The guidelines are reviewed continually and formally
released every 5 years. The AHA Guidelines were reviewed in
2010. Excellent CPR and early deﬁbrillation for fatal arrhythmias,
like VF and VT, are the ﬁrst steps of BTLS and ACLS. The new
Guidelines for ACLS emphasize that chest compressions should be
effective and continuous in order to achieve adequate cerebral and
coronary perfusion. The 2010 ACLS Guidelines strongly recom-
mend that every effort be made not to interrupt CPR [60]. These
changes should be included in the CMO training. Although the ISS
tries to follow the AHA Guidelines, it falls short in many areas—
drugs (amiodarone), exhaled CO2 detectors, etc. (Table 2) [58].
11. Comparisons between ISS treatments and hospital
treatments
Fortunately, crewmembers of the ISS have never experienced
an emergency that required ACLS. ISS crewmember candidates are
required to receive training in BLTS and ACLS before they go on a
mission; however, microgravity produces many conditions that are
different from Earth. For example, a bubble in a bag of normal
saline does not disappear to the “top of the bag” in microgravity.
Intravenous drip bags have to be squeezed by placing the bag in a
blood pressure cuff with a pressure of 50–70 mmHg [58]. More-
over, whereas doctors in the emergency room can use a video
laryngoscope for endotracheal intubation and exhaled CO2 detec-
tors to prevent esophageal intubation, the crewmembers in the ISS
must perform endotracheal intubation by using the old laryngo-
scopic method without exhaled CO2 detectors, which may result in
esophageal intubation. There are two reasons why the crewmem-
bers cannot use CO2 detectors. First, it is difﬁcult to read the
colorimetric end-tidal CO2 in the low ambient light of the ISS [58].
Second, the results of the colorimetric end-tidal CO2 are not
reliable because the CO2 level in the ISS is higher than that at
ground level. For the above reasons, an esophageal detector bulb is
provided in the ISS [58].
In the ISS, due to packing and storage issues, there are just
three drugs (epinephrine, lidocaine, and atropine) for ACLS com-
pared to the dozen or so drugs available to emergency room
doctors. This is not nearly enough [58]. As new evidence for drug
use with ACLS has accumulated, the revised ACLS guidelines state:
Fig. 8. Medical training for the crew in the ISS mock-up at the Johnson Space
Center. Photo courtesy of NASA/JAXA.
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“Atropine is no longer recommended for routine use and has been
removed from the cardiac arrest algorithm.” On the other hand,
recent studies showed amiodarone could be a key drug for treating
cardiac arrest, especially in VF and VT [61]. It may be an effective
countermeasure for fatal arrhythmias to provide amiodarone in
the ISS, instead of atropine.
New ACLS guidelines emphasize the importance of external
chest compressions (ECCs), stressing that ECCs should be per-
formed to the correct depth and frequency to guarantee effective-
ness [61]. Without gravity, the crewmembers cannot do ECCs in
the same way as in a hospital because of Newton's third law of
motion (action–reaction law). There are several studies about CPR
in spacecraft and three methods of performing CPR have been
introduced: the headstand method, the reverse bear hug method,
and the Evetts–Russomano method [62]. A recent study of ECCs
used parabolic ﬂight, which can provide 22 s of microgravity. This
study showed that the depth and frequency of the ECCs (Evetts–
Russomano method) achieved during the microgravity parabolas
were in accordance with the guidelines set by the AHA [63]. In
another study, investigators simulated microgravity via full body
suspension. This study indicated that the Evetts–Russomano
method may be an effective single-person CPR method for up to
3 min. However, the depth of chest compressions rapidly
decreases in simulated microgravity compared with 1 g [64].
Therefore, if CPR is continued for more than several minutes,
manual chest compressions become less effective and will con-
tinue to be so. Therefore, an automatic chest compression device
may be a great countermeasure for cardiac arrest. A recent study
used the “Auto Pulse”, which is a band chest compression device
for CPR, and showed that the “Auto Pulse” could improve the
tissue perfusion in patients with cardiac arrest. A band chest
compression device may help crewmembers to perform CPR in
spaceﬂight [65].
12. Potential countermeasures for arrhythmias during long-
duration spaceﬂight
After many years of practical and clinical research in the ﬁeld of
cardiology, we have compiled the following suggestions. Here are
several countermeasures for arrhythmias during long-duration
spaceﬂights that are sure to be effective.
A remote medical system will help to detect fatal arrhythmias
in astronauts during the early stages. JAXA is in the process of
developing a Remote Medical System [66]. This system consists of
an electric stethoscope, pulse oximeter, Holter-ECG, sleep monitor
and USB camera. It will allow ﬂight surgeons to see the astronauts'
ECGs or Holter-ECGs and listen to their heartbeat from Earth. The
ﬂight surgeons can then not only identify the arrhythmias, but also
give instructions about the medications [66]. A conventional
stethoscope is not very effective at checking for subtle cardiac
murmurs in the ISS, because of the high ambient noise levels [58].
The new system could help to detect any recent cardiac murmurs
in space.
Another cause of arrhythmias can be excessive radiation, which
causes coronary arteriosclerosis. Coronary arteriosclerosis can be
one of the main causes of fatal arrhythmias and SCD during long
spaceﬂights. Avoiding excessive radiation is one possible counter-
measure. Another possible countermeasure to the effects of radia-
tion on the heart would be a diet rich in antioxidants, such as
vitamins E, C, A, and β-carotene. In fact, Scott Smith and colleagues
at JSC have shown that blood concentrations of some antioxidants,
such as vitamin E, are decreased during long-duration spaceﬂight
[67], while several in vitro studies have indicated that several
vitamins and supplements, such as vitamin E and co-enzyme Q10,
may be effective countermeasures against oxidative stress caused
by space radiation [68,69]. However, taking fresh fruits and
vegetables on long-duration missions would be nearly impossible.
Furthermore, it appears that vitamins and other supplements lose
their stability during extended periods of spaceﬂight [70].
Another possibility is for the astronauts to grow their produce
in space. However, cultivation in a spacecraft is difﬁcult because of
the water restrictions.
Unfortunately, shielding the spacecraft is not a feasible option
with current technology and limitations on energy production and
consumption. Perhaps in the future, we will be able to develop a
shielding material that will be light enough and energy efﬁcient
enough to use for that purpose.
Another countermeasure for reducing the occurrence of SCD
and AF is a healthy intake of omega-3 fatty acids. In a systematic
review and meta-analysis of data pooled from 19 large prospective
cohort studies and randomized trials, it was shown that omega-3
fatty acids reduce ischemic heart death and SCD [71].
Some observational studies have found an association between
ﬁsh oil consumption and a reduced risk of AF [72]. These studies
prove that a healthy diet including omega 3 fatty acids will not
only reduce the risk of SCD, but also decrease the risk of ischemic
heart deaths [71].
When considering the causes of arrhythmias, we should also
place importance on a proper potassium intake and the adequate
intake of essential minerals (like magnesium). This is an important
Table 2
Comparison of current medical treatment in spacecraft and hospitals on Earth.
Spacecraft (ISS) Hospital
Body ﬁxing Crew medical restraint system
[59]
CPR board
Airway Bag-valve mask ventilation
(100% oxygen)
Bag-valve mask ventilation
Endotracheal intubation [74] (100% oxygen)
Intubating laryngeal mask
airway [74]
Endotracheal intubation
Esophageal detector bulb [58] Video laryngoscope
Colorimetric end-tidal CO2
Ventilation Respiratory ventilation [74] Positive airway pressure
ventilation
Respiratory ventilation
Fluid route Intravenous drip (IV)n Intravenous drip (IV)
Intraosseous drip (IO)n Intraosseous drip (IO)
nContinuous pressure is
required.
ACLS drug Epinephrine [58] Epinephrine
Lidocaine [58] Lidocaine
Atropine [58] Atropine
Amiodarone
Vasopressin
Magnesium sulfate
Sodium bicarbonate
Shock Automated external deﬁbrillator Deﬁbrillator (biphasic max
360 J)
(biphasic max 360 J) [58]
Monitor Lightweight trauma module ECG monitor
(12-lead ECG, automatic blood
pressure)
Blood pressure (cuff/arterial)
Oxygen saturation monitor
Respiratory monitor
Exhaled CO2 detectors
Ultrasound Advanced diagnostic
ultrasound microgravity
Echocardiography
Echocardiography [75]
Other
treatments
None Radiofrequency catheter
ablation
Pacemaker
Implantable cardioverter-
deﬁbrillator
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countermeasure, because astronauts tend to lose some of the
vitamins and minerals that are necessary for normal heart func-
tion during long spaceﬂights. Hypokalemia may be associated with
magnesium depletion (due, for example, to diuretics or diarrhea),
both of which lead to the development of arrhythmias. Hypoka-
lemia and hypomagnesemia are associated with an increased risk
of TdP, particularly in patients treated with drugs that prolong the
QT interval or those with a genetic predisposition to LQTS. In
addition to its direct proarrhythmic effect, hypomagnesemia can
increase urinary potassium losses and lower the concentration of
serum potassium.
13. Conclusion
There are many obstacles to long-duration spaceﬂights. The
crewmembers will have to face many physical problems in the
future that they have never experienced on the ISS missions so far.
Cardiac arrhythmias are one of the biggest medical and physical
problems that have to be overcome in the future. There are several
genes that could potentially cause fatal arrhythmias during long-
duration ﬂights, such as the LQT and Brugada syndromes. There-
fore, genetic tests might be added to the present cardiac screening
examinations of astronauts for a Mars mission in the future. New
drugs and devices will also be important factors in preventing
arrhythmias during long-duration ﬂights. However, we believe
that humankind is destined to explore new frontiers in space and
develop new techniques, equipment, and medical treatment to
adapt humans to the new frontier.
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